Preferences and perspectives of MS nurses and patients with multiple sclerosis regarding the new RebiSmart® 3.0 autoinjector versus other assistive devices

Author:

Colten Sridevi1,Cantogno Elisabetta Verdun1,Jack Dominic2

Affiliation:

1. EMD Serono Research and Development Institute, Inc. (an affiliate of Merck KGaA)

2. Merck Serono Ltd. (an affiliate of Merck KGaA)

Abstract

Abstract Background RebiSmart® is an electromechanical multidose autoinjector developed for administering subcutaneous interferon β-1a in patients with multiple sclerosis (pwMS). This online survey aimed to understand MS nurses’ and pwMS preferences and perceptions regarding the features of an upgraded version of the RebiSmart device (RebiSmart 3.0) compared to other assistive devices used for multiple sclerosis (MS) therapy. Patients and methods: Eligible MS nurses and pwMS from Germany, Italy, and the United Kingdom completed a double-blind, 30-minute online self-administered questionnaire, including a 10-minute video describing the features of RebiSmart 3.0 and its use in administering interferon β-1a. Results In total, 102 participants (MS nurses, n = 52; patients, n = 50) completed the survey. Overall, 70% respondents found the RebiSmart 3.0 device “very”/“extremely” appealing, 53% were “very”/“extremely” interested in learning more, and 71% stated they would be “very”/“extremely” comfortable using (pwMS) or educating (MS nurses) on it. Respondents ranked customizable injection process (including injection speed, hold time, depth and rotation guide), self-injection process, and hidden needle as the most important self-assistive device features. RebiSmart 3.0 was rated higher than other self-injecting devices on all tested features. After reviewing the video, 52% respondents had no questions, 67% nurses recommended providing more information on the customizable injection process feature of RebiSmart 3.0 to patients, and 88% nurses considered patient demonstration materials to be the most helpful type of information for them when initiating and educating pwMS on self-assistive devices. Conclusions The overall reactions of MS nurses and pwMS to the RebiSmart 3.0 device features were positive. The incremental advances over previous versions of the device as well as in comparison with other currently available assistive devices were welcomed. The MS nurses identified key needs for patient education on the use of the device and the suitable approaches (training videos and educational leaflets) to support MS nurses and pwMS.

Publisher

Research Square Platform LLC

Reference24 articles.

1. Multiple sclerosis;Filippi M;Nat Rev Dis Primers,2018

2. Treatment selection and experience in multiple sclerosis: survey of neurologists;Hanson KA;Patient Prefer Adherence,2014

3. placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group;Randomised double-blind;Lancet,1998

4. Long-term efficacy of interferon-beta-1a in relapsing MS;PRISMS-4;Neurology,2001

5. Risk Factors for Suboptimal Medication Adherence in Persons With Multiple Sclerosis: Development of an Electronic Health Record-Based Explanatory Model for Disease-Modifying Therapy Use;Gromisch ES;Arch Phys Med Rehabil,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3